Figure 3.
Analysis of survival and cumulative risk of relapse and early death for final low-risk patients with ALL who didn’t meet the criteria for the second dose of daunorubicin.
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.